Cardiotoxicity of Adjuvant Trastuzumab

Inclusion Criteria

• •Female 18 years or older
• •Histologically confirmed, completely excised invasive breast cancer with Her-2 overexpression
• •Primary surgery less than twelve weeks prior to registration
• •LVEF\>50% as assessed by transthoracic echocardiogram or gated heart pool scan
• •Eastern Cooperative Oncology Group Performance Status 0-2
• •Adjuvant systemic treatment plan comprises at least three cycles of anthracycline chemotherapy AND 52 weeks of trastuzumab
• •Before patient registration, informed consent must be given according to local regulations.